135 related articles for article (PubMed ID: 8940864)
21. Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer's disease.
Mouton-Liger F; Paquet C; Dumurgier J; Lapalus P; Gray F; Laplanche JL; Hugon J;
Biol Psychiatry; 2012 May; 71(9):829-35. PubMed ID: 22281122
[TBL] [Abstract][Full Text] [Related]
22. [Diagnostic value of tau in cerebrospinal fluid in alzheimer disease].
Hu Y; He S; Wang J
Zhonghua Yi Xue Za Zhi; 2001 Nov; 81(22):1377-9. PubMed ID: 11930632
[TBL] [Abstract][Full Text] [Related]
23. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.
Heslegrave A; Heywood W; Paterson R; Magdalinou N; Svensson J; Johansson P; Öhrfelt A; Blennow K; Hardy J; Schott J; Mills K; Zetterberg H
Mol Neurodegener; 2016 Jan; 11():3. PubMed ID: 26754172
[TBL] [Abstract][Full Text] [Related]
24. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
Hampel H; Buerger K; Zinkowski R; Teipel SJ; Goernitz A; Andreasen N; Sjoegren M; DeBernardis J; Kerkman D; Ishiguro K; Ohno H; Vanmechelen E; Vanderstichele H; McCulloch C; Moller HJ; Davies P; Blennow K
Arch Gen Psychiatry; 2004 Jan; 61(1):95-102. PubMed ID: 14706948
[TBL] [Abstract][Full Text] [Related]
25. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.
Buerger K; Zinkowski R; Teipel SJ; Tapiola T; Arai H; Blennow K; Andreasen N; Hofmann-Kiefer K; DeBernardis J; Kerkman D; McCulloch C; Kohnken R; Padberg F; Pirttilä T; Schapiro MB; Rapoport SI; Möller HJ; Davies P; Hampel H
Arch Neurol; 2002 Aug; 59(8):1267-72. PubMed ID: 12164722
[TBL] [Abstract][Full Text] [Related]
26. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
27. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
[TBL] [Abstract][Full Text] [Related]
28. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols.
Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Giau VV; Bagyinszky E; Lim KT; Kang SM; An SS; Park YH; Youn YC; Kim S
J Alzheimers Dis; 2016 May; 52(4):1403-13. PubMed ID: 27163824
[TBL] [Abstract][Full Text] [Related]
29. Increased cerebrospinal fluid tau in patients with Alzheimer's disease.
Jensen M; Basun H; Lannfelt L
Neurosci Lett; 1995 Feb; 186(2-3):189-91. PubMed ID: 7777193
[TBL] [Abstract][Full Text] [Related]
30. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study.
Andreasen N; Vanmechelen E; Van de Voorde A; Davidsson P; Hesse C; Tarvonen S; Räihä I; Sourander L; Winblad B; Blennow K
J Neurol Neurosurg Psychiatry; 1998 Mar; 64(3):298-305. PubMed ID: 9527138
[TBL] [Abstract][Full Text] [Related]
31. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
Seppälä TT; Koivisto AM; Hartikainen P; Helisalmi S; Soininen H; Herukka SK
J Alzheimers Dis; 2011; 25(4):583-94. PubMed ID: 21460434
[TBL] [Abstract][Full Text] [Related]
32. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
[TBL] [Abstract][Full Text] [Related]
33. Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer's Disease.
Zimetti F; Caffarra P; Ronda N; Favari E; Adorni MP; Zanotti I; Bernini F; Barocco F; Spallazzi M; Galimberti D; Ricci C; Ruscica M; Corsini A; Ferri N
J Alzheimers Dis; 2017; 55(1):315-320. PubMed ID: 27662294
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease.
Valcárcel-Nazco C; Perestelo-Pérez L; Molinuevo JL; Mar J; Castilla I; Serrano-Aguilar P
J Alzheimers Dis; 2014; 42(3):777-88. PubMed ID: 24916543
[TBL] [Abstract][Full Text] [Related]
35. Cerebrospinal Fluid Biomarkers as a Diagnostic Tool of the Underlying Pathology of Primary Progressive Aphasia.
Paraskevas GP; Kasselimis D; Kourtidou E; Constantinides V; Bougea A; Potagas C; Evdokimidis I; Kapaki E
J Alzheimers Dis; 2017; 55(4):1453-1461. PubMed ID: 27858708
[TBL] [Abstract][Full Text] [Related]
36. Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia.
Nägga K; Gottfries J; Blennow K; Marcusson J
Dement Geriatr Cogn Disord; 2002; 14(4):183-90. PubMed ID: 12411760
[TBL] [Abstract][Full Text] [Related]
37. Tau protein in cerebrospinal fluid: a new diagnostic and prognostic marker in Alzheimer disease?
Mecocci P; Cherubini A; Bregnocchi M; Chionne F; Cecchetti R; Lowenthal DT; Senin U
Alzheimer Dis Assoc Disord; 1998 Sep; 12(3):211-4. PubMed ID: 9772026
[TBL] [Abstract][Full Text] [Related]
38. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease.
Vigo-Pelfrey C; Seubert P; Barbour R; Blomquist C; Lee M; Lee D; Coria F; Chang L; Miller B; Lieberburg I
Neurology; 1995 Apr; 45(4):788-93. PubMed ID: 7723971
[TBL] [Abstract][Full Text] [Related]
39. Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan.
Nishimura T; Takeda M; Nakamura Y; Yosbida Y; Arai H; Sasaki H; Shouji M; Hirai S; Khise K; Tanaka K; Hamamoto M; Yamamoto H; Matsubayashi T; Urakami K; Adachi Y; Nakashima K; Toji H; Nakamura S; Yoshida H
Methods Find Exp Clin Pharmacol; 1998 Apr; 20(3):227-35. PubMed ID: 9646285
[TBL] [Abstract][Full Text] [Related]
40. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.
Dayon L; Wojcik J; Núñez Galindo A; Corthésy J; Cominetti O; Oikonomidi A; Henry H; Migliavacca E; Bowman GL; Popp J
J Alzheimers Dis; 2017; 60(4):1641-1652. PubMed ID: 29125490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
